Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment.

JAMA·2026
Same author

Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Neuropathological and functional impact of astrocyte-derived extracellular vesicles in an aged model of Alzheimer's disease.

Experimental neurology·2026
Same author

Retraction Note: Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells.

Experimental & molecular medicine·2026
Same author

Structural Basis for the Pro-amyloidogenic Action and Ligand Binding of a Novel W72R Variant of Human Apolipoprotein A-I.

Journal of molecular biology·2026
Same author

Sex-Dependent Effects of CSF1R-Mediated Myeloid Cell Depletion in a Mouse Model of Multiple System Atrophy.

The European journal of neuroscience·2026

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Rijwan Uddin Ahammad1, Brian Spencer1, Robert A Rissman1

  • 1Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括

一种针对Lewy体痴呆症 (DLB) 的新型针对α-synuclein (α-syn) 的治疗方法显示出有前途的结果. ApoB11的系统输送:ASOα-syn降低了α-syn聚合物,改善了认知和运动功能,并在小鼠中增强了神经元存活率.

科学领域:

  • 神经科学是一个神经科学.
  • 神经学 神经学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 勒维体痴呆症 (DLB) 涉及α-synuclein (α-syn) 和阿尔茨海默病 (AD) 病理,导致神经退行和认知能力下降.
  • 目前对DLB和相关疾病 (ADRD) 的治疗方法有限,没有可用的疾病修饰疗法.
  • α-syn 寡合体和原纤维素与突核蛋白病变的神经退行过程有关.

研究的目的:

  • 在DLB的小鼠模型中评估系统输送的ApoB11:2'-OMe ASO向α-syn的安全性和有效性.
  • 评估ASO治疗的药理动力学,药理动力学和毒理学特征.
  • 确定治疗对α-syn聚合,神经退行以及认知/运动缺陷的影响.

主要方法:

  • 利用了针对α-syn的2'-OMe修饰的反意义寡核酸 (ASO),与ApoB合以透血脑屏障.
  • 给DLB转基因和非转基因小鼠使用的ApoB11:2'-OMe ASO.
  • 通过使用qPCR,免疫组织化学,西斑和行为测试来评估治疗效应.

主要成果:

  • ApoB: 2'-OMe ASO向α-syn在DLB小鼠中耐受良好且安全,脑部输送成功,没有观察到毒性.
  • 在接受治疗的DLB小鼠的大脑中观察到α-syn聚合物的显著减少.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451
  • 改善了空间记忆和运动性能,伴随着增加的神经元存活率和减少神经退行.
  • 结论:

    • 系统输送的ApoB:ASOα-syn代表了对DLB的安全,改变疾病的治疗策略.
    • 这种方法显示出作为其他同核蛋白病变的未来治疗方法的潜力.
    • 向α-syn减少为治疗神经退行性疾病提供了一个有希望的途径.